Navigation Links
Antibody therapy lengthens survival of metastatic melanoma patients in large clinical trial
Date:6/7/2010

st other cancers. Associated with extended periods of exposure to ultraviolet rays in sunlight, the disease is expected to be diagnosed in more than 68,000 Americans and be responsible for 8,700 deaths in this country in 2010, according to the American Cancer Society. There are no approved therapies for metastatic melanoma beyond standard frontline treatments, and no previous therapy for the disease has been proven effective in a phase III clinical trial.

Ipilimumab, developed by Bristol-Myers Squibb and Medarex, consists of millions of copies of a human antibody that binds to a molecule on T cells white blood cells that patrol the body for signs of illness. The molecule, known as CTLA-4, serves as a control switch for the immune system's response to disease. With no antibody attached, CTLA-4 suppresses the immune response. Ipilimumab reverses that condition, unleashing the immune attack on abnormal cells, including cancer cells. "It essentially takes a brake off the immune system," Hodi says.

The new phase III trial involved 676 patients with advanced (stage III or IV), inoperable melanoma that had worsened during prior therapy for metastatic disease. Patients were randomly assigned to receive one of three treatment regimens: ipilimumab and the gp100 vaccine (which seeks to spark an immune response by presenting the immune system with a protein fragment associated with cancer), ipilimumab alone, or gp 100 alone.

The median survival period for patients receiving ipilimumab plus gp100 was 10 months, compared with 6.4 months for those receiving gp100 alone. The median survival for participants receiving ipilimumab alone was 10.1 months. In the ipilimumab-alone group, nine of 15 patients continued to benefit from the therapy for at least two years, as did four of 23 patients in the combination therapy group.

About 60 percent of the patients treated with ipilimumab experienced adverse side effects to the therapy, as did 32 pe
'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-233-5507
Dana-Farber Cancer Institute
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Antibody-guided drug shows encouraging activity in metastatic breast cancer
2. Fox Chase clinical trial tests first of its kind antibody
3. Targeted therapy prolongs life in patients with HER2-positive breast cancer
4. PharmMD Secures Investments to Fund New Opportunities in Medication Therapy Management
5. More smokers kick the habit with extended nicotine patch therapy, Penn research shows
6. Experts Issue Warning on Prostate Hormone Therapy
7. ASGCT: Gene Therapy Shows Promise for Patients with Pompe Disease
8. AAPM statement on quality radiation therapy
9. Congress Urged to Take Immediate Action to Ensure Frail Patients Continue to Receive Critical Therapy Services
10. Intensive Insulin Therapy Wont Boost Septic Shock Survival
11. News brief: Dermatologic infections in cancer patients treated with EGFRI therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... (PRWEB) September 22, 2014 TherapySites ... titled "From Divorce Talk to Solution Talk: Solution Focused ... The 60-minute webinar, presented by special guest speaker Elliott ... 1pm Central Standard Time. , Reserve Your Seat ... Solution Talk: Solution Focused Brief Therapy with the Most ...
(Date:9/22/2014)... The Ruby Report was launched by ... International Conference in Louisville, Kentucky. This release followed the ... a reception attended by 60 people from the local ... had gained while conducting her research, what drove her ... issue, and what she believes companies can do to ...
(Date:9/21/2014)... CA (PRWEB) September 22, 2014 CareSpan ... it has entered into a joint services agreement with ... Dakota, to deploy the CareSpan Virtual Clinic in multiple ... Avera eCARE plan to deploy their joint services in ... and Wyoming where Avera eCARE is licensed. The two ...
(Date:9/21/2014)... September 22, 2014 UNIWIGS, one of the ... extensions and hair pieces, offers a line of human hair ... trend and it also shows people what the latest ... famous star Rihanna, there are 4 different hairstyles to choose ... of ombre wave lace wigs and a hot ombre red ...
(Date:9/21/2014)... September 21, 2014 More than a quarter of ... dryer fires start in one of two ways. The first ... out properly. The second type of dryer fire occurs when ... (Dryers can also catch fire due to malfunctioning electrical systems so ... to take a look!) Here are some ways that you ...
Breaking Medicine News(10 mins):Health News:TherapySites Presents a Webinar, "From Divorce Talk to Solution Talk: Solution Focused Brief Therapy with the Most Trying of Couples Sessions” with Elliott Connie 2Health News:TherapySites Presents a Webinar, "From Divorce Talk to Solution Talk: Solution Focused Brief Therapy with the Most Trying of Couples Sessions” with Elliott Connie 3Health News:Ruby Report Book Launch Reveals Critical Insights on Gender Intelligence 2Health News:Avera eCARE and CareSpan form Collaboration to Deliver “Virtualized” Primary Care in the Dakotas and Wyoming 2Health News:Avera eCARE and CareSpan form Collaboration to Deliver “Virtualized” Primary Care in the Dakotas and Wyoming 3Health News:UniWigs New Arrivals Just In- Human Hair Lace Wigs Inspired By Famous Celebrities 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 3
... and more than 300 people in the UK die from ... permanent disabilities. Now researchers will work on a potential vaccine ... medical charity Meningitis UK. , Although vaccines exist to protect ... to protect against all strains, including the most common in ...
... Immediate Moratorium on Bisphenol,A in Baby Bottles, Food and ... Dozens of state,and national environmental health organizations in the ... the use of bisphenol A (BPA) in baby,bottles and ... of a,new study that demonstrates the toxic chemical BPA ...
... intramuscular injection, study says , , THURSDAY, Feb. 7 ... for delivering DNA vaccines than intramuscular injection, a new ... Genetic Vaccines and Therapy , researchers at the ... protein from the human papillomavirus (HPV), which causes cervical ...
... operating results for the fourth quarter and year ended December 31,2007., Fourth ... $6.883 billion. -- Net income totaled $278 million, ... prior year. -- Adjusted EBITDA totaled $1.153 ... in the prior year. -- Provision for doubtful ...
... DURHAM, NC A novel drug designed to lessen muscle ... at the Duke Clinical Research Institute. Results of the study, ... issue of the journal Circulation, reflect the first time the ... known as KAI-9803, blocks the activity of an enzyme called ...
... 7 Anthera Pharmaceuticals,Inc., a privately held biopharmaceutical ... the Phase II trial,of its novel secretory phospholipaseA2 ... disease will be presented as a late breaker,at ... Scientific Session,on Monday, March 31, 2008 in Chicago, ...
Cached Medicine News:Health News:Meningitis vaccine study gets £200,000 boost 2Health News:Baby Bottles Leach Toxic Chemical, According to New U.S. and Canadian Study 2Health News:Baby Bottles Leach Toxic Chemical, According to New U.S. and Canadian Study 3Health News:Baby Bottles Leach Toxic Chemical, According to New U.S. and Canadian Study 4Health News:Tattooing Best Way to Deliver DNA Vaccines 2Health News:HCA Reports Fourth Quarter - Year End 2007 Results 2Health News:HCA Reports Fourth Quarter - Year End 2007 Results 3Health News:HCA Reports Fourth Quarter - Year End 2007 Results 4Health News:HCA Reports Fourth Quarter - Year End 2007 Results 5Health News:HCA Reports Fourth Quarter - Year End 2007 Results 6Health News:HCA Reports Fourth Quarter - Year End 2007 Results 7Health News:HCA Reports Fourth Quarter - Year End 2007 Results 8Health News:HCA Reports Fourth Quarter - Year End 2007 Results 9Health News:HCA Reports Fourth Quarter - Year End 2007 Results 10Health News:HCA Reports Fourth Quarter - Year End 2007 Results 11Health News:HCA Reports Fourth Quarter - Year End 2007 Results 12Health News:HCA Reports Fourth Quarter - Year End 2007 Results 13Health News:HCA Reports Fourth Quarter - Year End 2007 Results 14Health News:HCA Reports Fourth Quarter - Year End 2007 Results 15Health News:Novel compound may lessen heart attack damage 2Health News:Data From Anthera's Plasma Trial to be Presented as Late Breaker at American College Of Cardiology Scientific Sessions 2
(Date:9/19/2014)... , Sept. 19, 2014  Diplomat, the nation,s ... David Dreyer to the Board of Directors ... director and will also serve as chair of the ... 30 years of accounting, financial, compliance and operating experience ... Dreyer has served as chief financial officer, chief operating ...
(Date:9/19/2014)... -- Five MinuteClinic walk-in medical clinics are opening inside select CVS/pharmacy ... clinics opened in Memphis and ... added in Springfield on September 24 and ... to open October 22.  MinuteClinic is the largest and fastest growing ... . The Memphis -area clinics ...
(Date:9/19/2014)... , September 19, 2014 ... Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), Industry ... (Tray-style, Manifold, & Rotary) & Geography - Global ... defines and segments the lyophilization market on the ... analyses and projections of the market size of ...
Breaking Medicine Technology:David Dreyer Appointed to Diplomat Board of Directors 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3
... Mindray Medical International Limited (NYSE: MR ... devices worldwide, announced today an agreement to acquire a ... The terms of the agreement were not disclosed as ... Founded in 2003 and based in Suzhou, China, ...
... NEWARK, N.J., July 5, 2011 Regulators are ... punish corporate officers they suspect of wrongdoing—in effect, ... their jobs. It is unclear whether they intend ... dubbed the "death penalty" by some—but at a ...
Cached Medicine Technology:Mindray Medical to Acquire a Controlling Stake in Suzhou Hyssen Electronics 2Mindray Medical to Acquire a Controlling Stake in Suzhou Hyssen Electronics 3Feds Might 'Banish' More Execs for Misconduct, Attorney Says 2Feds Might 'Banish' More Execs for Misconduct, Attorney Says 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: